Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial

Dickerson, Faith; Adamos, Maria; Katsafanas, Emily; Khushalani, Sunil; Origoni, Andrea; Savage, Christina; Schweinfurth, Lucy; Stallings, Cassie; Sweeney, Kevin; Goga, Joshana; Yolken, Robert H.

doi:10.1111/bdi.12652

Cited by 109 publications

(82 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the same research group further reported that 3‐month supplement with this probiotic formula could improve of performance concerning attention, psychomotor processing speed, and executive function in euthymic patients with BD 78 . Another study suggested that adjunctive probiotic supplement ( Lactobacillus GG strain and Bifidobacterium lactis strain) reduced the rehospitalization rate in patients who were recently discharged for mania 79 . Although the exact mechanisms by which probiotic microorganisms benefit for mental health remain unknown, it is possible that they reconstruct the gut microbiota and modulate host immune reactions in response to various antigens 75 .…”

Section: Future Directionsmentioning

confidence: 99%

Gut microbial clues to bipolar disorder: State‐of‐the‐art review of current findings and future directions

Lai

Jiang

Zhang

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

Trillions of microorganisms inhabiting in the human gut play an essential role in maintaining physical and mental health. The connections between gut microbiome and neuropsychiatric diseases have been recently identified. The pathogenesis of bipolar disorder, a spectrum of diseases manifesting with mood and energy fluctuations, also seems to be involved in the bidirectional modulation of the microbiome‐gut‐brain (MGB) axis. In this review, we briefly introduce the concept of MGB axis, and then focus on the previous findings in human studies associated with bipolar disorder. These studies provided preliminary evidences on the gut microbial alterations in bipolar disorder. Limitations in these studies and future directions in this research field, such as fecal microbiome transplantation and microbiome‐targeted therapy, were discussed. A research framework linking gut microbiome to determinants and health‐related outcomes in BD was also proposed. Better characterizing and understanding of gut microbial biosignatures in bipolar patients contribute to clarify the etiology of this intractable disease and pave the new way for treatment innovation.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Gut microbial clues to bipolar disorder: State‐of‐the‐art review of current findings and future directions

Lai

Jiang

Zhang

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…Thus, we cannot determine whether observed microbial changes are due to treatment or other potential sources of bias. Earlier randomized, double-blinded, placebo-controlled trials investigating probiotic interventions in SMI have reported to improve bowel function (Dickerson et al, 2014), reduce levels of intestinal inflammatory indices (Severance et al, 2017), and increase levels of systemic immunomodulatory proteins (Tomasik et al, 2015), but the findings with regards to psychiatric outcomes are still mixed (Dickerson et al, 2018(Dickerson et al, , 2014Severance et al, 2017). These studies did not assess microbial biomarkers pre-or post-treatment, so the relationship of the immune and clinical responses to gut microbial composition remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

Nguyen

Hathaway

Kościółek

et al. 2021

Schizophrenia Research

View full text Add to dashboard Cite

Schizophrenia and bipolar disorder (BD) are associated with debilitating psychiatric and cognitive dysfunction, worse health outcomes, and shorter life expectancies. The pathophysiological understanding of and therapeutic resources for these neuropsychiatric disorders are still limited. Humans harbor over 1000 unique bacterial species in our gut, which have been linked to both physical and mental/cognitive health. The gut microbiome is a novel and promising avenue to understand the attributes of psychiatric diseases and, potentially, to modify them. Building upon our previous work, this systematic review evaluates the most recent evidence of the gut microbiome in clinical populations with serious mental illness (SMI). Sixteen articles that met our selection criteria were reviewed, including cross-sectional cohort studies and longitudinal treatment trials. All studies reported alterations in the gut microbiome of patients with SMI compared to non-psychiatric comparison subjects (NCs), and beta-diversity was consistently reported to be different between schizophrenia and NCs. Ruminococcaceae and Faecalibacterium were relatively decreased in BD, and abundance of Ruminococcaceae was reported across several investigations of SMI to be associated with better clinical characteristics. Lactic acid bacteria were relatively more abundant in SMI and associated with worse clinical outcomes. There was very limited evidence for the efficacy of probiotic or prebiotic interventions in SMI. As microbiome research in psychiatry is still nascent, the extant literature has several limitations. We critically evaluate the current data, including experimental approaches. There is a need for more unified methodological standards in order to arrive at robust biological understanding of microbial contributions to SMI.

show abstract

“…The Lactobacillus casei and Bifidobacteria groups are some of the most widely researched and applied probiotic species (Hill et al, ). The health‐promoting capabilities of these probiotics have been documented in child asthma (Kalliomaki et al, ), mania (Dickerson et al, ), and obesity (Luoto, Kalliomaki, Laitinen, & Isolauri, ). Previous research has shown that administration of Lactobacillus acidophilus in the gut results in analgesic effects in rodents similar to those observed with morphine (Rousseaux et al, ) and that the Escherichia coli strain Nissle 1917 provided analgesia for the visceral pain associated with irritable bowel syndrome (Perez‐Berezo et al, ).…”

Section: Discussionmentioning

confidence: 99%

OralLactobacillus reuteriLR06 orBifidobacteriumBL5b supplement do not produce analgesic effects on neuropathic and inflammatory pain in rats

et al. 2019

View full text Add to dashboard Cite

Background Previous studies have reported that certain bacteria exert visceral antinociceptive activity in visceral pain and may also help to relieve neuropathic and inflammatory pain. Objective: The aim of this study was to explore the analgesic effect of Lactobacillus reuteri LR06 (LR06) or Bifidobacterium BL5b (BL5b) in chronic pain in vivo. Design Rats were randomly assigned into four groups: sham, Chronic Constriction Injury (CCI)/Complete Freund's Adjuvant (CFA) + control, CCI/CFA + LR06, and CCI/CFA + BL5b. Rats from the probiotic groups were treated with 1 x 109 cfu (LR06 or BL5b) daily through gavage for 14 days after a pain model was successfully established. Mechanical and thermal hyperalgesia were used to assess the analgesic effect of the probiotics. Iba1 was used to verify the microglial inflammatory reaction in the different groups. Results The results showed that probiotics L. reuteri LR06 or Bifidobacterium BL5b had no significant antinociception effects in chronic pain rats. The chronic pain‐induced activation of microglia (Iba1) was not relieved by probiotics in CCI/CFA‐induced neuropathic or inflammatory pain rats. Conclusion Our results suggested that L. reuteri LR06 or Bifidobacterium BL5b had no antinociceptive effects on CCI‐induced neuropathic pain and CFA‐induced inflammatory pain in rats.

show abstract

Adjunctive probiotic microorganisms to prevent rehospitalization in patients with acute mania: A randomized controlled trial

Abstract: Probiotic supplementation is associated with a lower rate of rehospitalization in patients who have been recently discharged following hospitalization for mania.

Cited by 109 publications

References 41 publications

Gut microbial clues to bipolar disorder: State‐of‐the‐art review of current findings and future directions

Gut microbial clues to bipolar disorder: State‐of‐the‐art review of current findings and future directions

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

OralLactobacillus reuteriLR06 orBifidobacteriumBL5b supplement do not produce analgesic effects on neuropathic and inflammatory pain in rats

Contact Info

Product

Resources

About